IRulya Therapeutics Inc.
Quince Therapeutics is a biotechnology company whose AIDE platform uses an automated drug-device system to encapsulate drugs in a patient’s own red blood cells. The system includes the RCL device and a sterile, single-use treatment kit, designed for drug processing at the point of care. Its lead candidate, eDSP, used the platform to encapsulate DSP and was studied for the rare disease A-T. After the Phase 3 NEAT trial did not meet its primary endpoint, Quince discontinued development of eDSP and has no other current product candidates. It has discontinued product development activities and is focused on preserving cash while evaluating strategic alternatives, including a possible reverse merger. Quince has a manufacturing facility in Medolla, Italy, producing and servicing RCL machines, treatment kits and other proprietary medical devices, and also uses third-party manufacturers for components and final assemblies. Its principal executive offices are in South San Francisco, California.
No SEC Form 4 filings for $IRLA in the last 30 days.
See all $IRLA insider activity →IRulya Therapeutics reported a Q3 2026 net loss of $27.7M, up from $13.4M a year earlier. Cash reserves totaled $105.2M. R&D expenses fell to $5.9M, while G&A expenses rose to $9.0M. The company's Phase 2 trial in BOS is fully enrolled, with results expected in Q1 2027. IRulya changed its name from Quince Therapeutics and converted its Series C preferred stock.
IRulya Therapeutics Inc. (IRLA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 IRulya Therapeutics Provides Corporate Update and Reports Third Quarter 2026 Financial Results Name changed from Quince Therapeutics, Inc. to IRulya Therapeutics Inc.; common stock began trading on the Nasdaq Capital Market under the ticker “IRLA” on October 12, 2026
IRulya Therapeutics (IRLA) released an updated corporate presentation with LAM-001 Phase 2 clinical data, including 6MWD +67.4m, PVR -35.3%, and NT-proBNP -28.8% at 24 weeks. Phase 2b PH-ILD data is expected in 1Q 2028, and Phase 2 BOS data in 1Q 2027. The company plans a Phase 2 SAPH trial starting 4Q 2026 with data anticipated in 4Q 2028. IRLA also highlighted its IP strategy and exclusivity plans.
Over the past 7 days, AlphAI's AI scored 3 news stories mentioning IRLA (IRulya Therapeutics Inc.). Coverage has skewed bearish: 1 bullish, 0 neutral, and 2 bearish.
Recent IRLA coverage spans corporate actions, earnings and technology.
The loss widens year‑over‑year and cash burn remains high, suggesting near‑term financing pressure.
Earnings miss and higher expenses likely weigh on the stock despite ample cash runway.
Positive Phase 2a results could lift the stock as investors reassess the drug's commercial potential.
Quince Therapeutics, Inc. (QNCX) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Exhibit 99.1 Quince Therapeutics Relaunches as IRulya Therapeutics with a Focus on the Clinical Development of LAM-001, Targeting a Key Pathway in Pulmonary Disease Company common stock to trade on Nasdaq under the symbol “IRLA” effective October 12, 2026 Key Management changes i
Raymond James initiated coverage on Quince Therapeutics (NASDAQ:QNCX) with an outperform rating and $72 price target, citing its LAM-001 drug for pulmonary diseases. The stock trades near its $30.41 fair value, with a $29.86M market cap and no expected profitability this year. Other analysts also gave positive ratings and targets. The company plans a stockholder meeting to vote on issuing shares, potentially changing control. LAM-001 remains a key focus.
AlphAI scores every news story that mentions IRLA with an AI model for sentiment and relevance, and aggregates insider trades from IRulya Therapeutics Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
IRulya Therapeutics reported a Q3 2026 net loss of $27.7M, up from $13.4M a year earlier. Cash reserves totaled $105.2M. R&D expenses fell to $5.9M, while G&A expenses rose to $9.0M. The company's Phase 2 trial in BOS is fully enrolled, with results expected in Q1 2027. IRulya changed its name from Quince Therapeutics and converted its Series C preferred stock.
IRulya Therapeutics Inc. (IRLA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 IRulya Therapeutics Provides Corporate Update and Reports Third Quarter 2026 Financial Results Name changed from Quince Therapeutics, Inc. to IRulya Therapeutics Inc.; common stock began trading on the Nasdaq Capital Market under the ticker “IRLA” on October 12, 2026
IRulya Therapeutics (IRLA) released an updated corporate presentation with LAM-001 Phase 2 clinical data, including 6MWD +67.4m, PVR -35.3%, and NT-proBNP -28.8% at 24 weeks. Phase 2b PH-ILD data is expected in 1Q 2028, and Phase 2 BOS data in 1Q 2027. The company plans a Phase 2 SAPH trial starting 4Q 2026 with data anticipated in 4Q 2028. IRLA also highlighted its IP strategy and exclusivity plans.
Quince Therapeutics, Inc. (QNCX) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Exhibit 99.1 Quince Therapeutics Relaunches as IRulya Therapeutics with a Focus on the Clinical Development of LAM-001, Targeting a Key Pathway in Pulmonary Disease Company common stock to trade on Nasdaq under the symbol “IRLA” effective October 12, 2026 Key Management changes i
Raymond James initiated coverage on Quince Therapeutics (NASDAQ:QNCX) with an outperform rating and $72 price target, citing its LAM-001 drug for pulmonary diseases. The stock trades near its $30.41 fair value, with a $29.86M market cap and no expected profitability this year. Other analysts also gave positive ratings and targets. The company plans a stockholder meeting to vote on issuing shares, potentially changing control. LAM-001 remains a key focus.
Quince Therapeutics, Inc. (QNCX) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On October 6, 2026, Quince Therapeutics, Inc. (the “ Company ”), held a special meeting of stockholders (the “ Special Mee
Quince Therapeutics, Inc. (QNCX) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On September 30, 2026, each of June Bray, David Lamond and Christopher Senner (collectively, the “ Resigning Directors ”)
Citizens upgraded Quince Therapeutics (QNCX) to Market Outperform with a $77 price target, citing its rare disease pipeline and undervaluation. The company's LAM-001 drug is in Phase 2 trials for pulmonary diseases, with a potential market of 200,000 patients in the U.S. and Europe. QNCX shares have risen ~94% in six months, and the company plans a stockholder meeting to vote on share issuance.
Quince Therapeutics, Inc. (QNCX) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. Exhibit 99.1 UNAUDITED PRO FORMA CONDENSED CONSOLIDATED FINANCIAL INFORMATION Quince Therapeutics, Inc., a Delaware corporation (the "Company” or "Seller"), Quince Therapeutics SpA, a company organized under the laws of Italy ("Quince SPA", "Italian Subsidiary") entered into an a
Quince Therapeutics' President Charles Ryan will leave the company on September 8, 2026, according to an SEC filing. The reason for his departure and any replacement details were not disclosed.
